Arsenal Biosciences has cleared an impressive $325 million from a third-round financing that will be used to fund clinical trials of its pipeline of CAR-T therapies, trying to break new gro
Researchers in the Netherlands have developed 3D-printed 'mini tumours' that behave like real cancerous tissue and can be used to test new treatments, including drug and cell-based immunoth
Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to
MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M
Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.
Johnson & Johnson's Balversa has become the first drug approved in the EU to treat adults with advanced urothelial carcinoma (mUC) with FGFR3 genetic alterations after one line of prior
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.